Company Renalytix Plc

Equities

RENX

GB00BYWL4Y04

Advanced Medical Equipment & Technology

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Renalytix Plc

Quarterly revenue - Rate of surprise

Sector Medical Diagnostic & Testing Equipment

Market Closed - London S.E. Other stock markets 09:05:00 30/04/2024 pm IST			5-day change	1st Jan Change
21.5 ^GBX	-10.42%		-25.86%	+38.71%

18/04	Renalytix chief business officer to become president	AN
18/04	Renalytix Names Chief Business Officer as President	MT

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Companyâs lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Number of employees: 102

GBP in Million	2022	Weight	2023	Weight	Delta
Artificial Intelligence-enabled in Vitro Diagnostics 100.0 %	2	100.0 %	3	100.0 %	+26.61%

GBP in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	2	100.0 %	3	100.0 %	+26.61%

Managers	Title	Age	Since
James McCullough FOU	Founder	56	15/18/15
James Sterling DFI	Director of Finance/CFO	54	15/18/15
Thomas McLain PSD	President	66	29/19/29
Fergus Fleming CTO	Chief Tech/Sci/R&D Officer	57	15/18/15
Michael Donovan CTO	Chief Tech/Sci/R&D Officer	70	15/18/15
Joseph Hutson PRN	Corporate Officer/Principal	-	22/21/22
Andria Parks-Herrera SAM	Sales & Marketing	-	07/21/07
Salim Hamir SEC	Corporate Secretary	-	-
Jed Fulk SAM	Sales & Marketing	64	07/21/07
Howard Doran PRN	Corporate Officer/Principal	63	01/23/01

Members of the board	Title	Age	Since
Daniel Levangie BRD	Director/Board Member	73	30/21/30
Christopher Mills CHM	Chairman	72	15/18/15
James McCullough FOU	Founder	56	15/18/15
Fergus Fleming CTO	Chief Tech/Sci/R&D Officer	57	15/18/15
Erik Lium BRD	Director/Board Member	56	01/18/01
Catherine Coste BRD	Director/Board Member	58	30/23/30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	154,368,191	110,735,634 ( 71.73 %)	0	71.73 %

Name	Equities	%	Valuation
The Mount Sinai Hospital 24.00 %	23,979,726	24.00 %	10 M p
Polar Capital LLP 13.88 %	13,866,061	13.88 %	6 M p
Christopher Mills 10.08 %	10,072,500	10.08 %	4 M p
Jefferson River Capital LLC 8.539 %	8,533,280	8.539 %	4 M p
Heights Capital Management, Inc. 8.296 %	8,289,992	8.296 %	4 M p
Susquehanna Investment Group LLC 7.869 %	7,863,212	7.869 %	3 M p
Pentwater Capital Management LP 5.789 %	5,785,196	5.789 %	2 M p
Nathaniel Rothschild 4.004 %	4,001,187	4.004 %	2 M p
NR Holdings Ltd. (United Kingdom) 4.004 %	4,001,187	4.004 %	2 M p
Lombard Odier Asset Management (Europe) Ltd. 4.003 %	4,000,000	4.003 %	2 M p

Name	Equities	%	Valuation
Jefferson River Capital LLC 8.539 %	4,266,640	8.539 %	4 M p
Pentwater Capital Management LP 2.522 %	1,260,000	2.522 %	1 M p
CVI Holdings LLC 2.290 %	1,144,305	2.290 %	984 102 p
Gilder, Gagnon, Howe & Co. LLC 1.760 %	879,451	1.760 %	756 328 p
Pentwater Capital Management LP 1.401 %	700,000	1.401 %	602 000 p
Pinnacle Associates Ltd. 1.393 %	696,005	1.393 %	598 564 p
Tejara Capital Ltd. 0.8013 %	400,394	0.8013 %	344 339 p
Corient Private Wealth LLC 0.6715 %	335,514	0.6715 %	288 542 p
Gofen & Glossberg LLC 0.3767 %	188,224	0.3767 %	161 873 p
Lazard Asset Management LLC 0.2734 %	136,620	0.2734 %	117 493 p

Renalytix Plc

1460 Broadway

10036, New York

+646 397 3970

http://www.renalytixai.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.215

Average target price

Consensus

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Advanced Medical Equipment & Technology

Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
RENALYTIX PLC	+38.71%	46.5M
SARTORIUS AG	-15.28%	19.22B
QUIDELORTHO CORPORATION	-44.98%	2.63B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+17.00%	1.86B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-0.51%	1.66B
BIOTAGE AB	+25.65%	1.23B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-13.90%	1.05B
CONTEC MEDICAL SYSTEMS CO.,LTD	-21.76%	894M
REVENIO GROUP OYJ	-3.53%	740M
VAREX IMAGING CORPORATION	-20.73%	687M

Medical Diagnostic & Testing Equipment